The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis

Scandinavian Journal of Immunology

Volumn 68, Issue 6, 2008, Pages 661-667

  Forsblad D'Elia, H ^a,b   Carlsten, H ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; COLECALCIFEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESTRADIOL; GLUCOCORTICOID; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; NORETHISTERONE ACETATE; PREDNISOLONE; RHEUMATOID FACTOR; TUBERCULIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IN VIVO STUDY; INFLUENZA; INFLUENZA VACCINATION; LOW DRUG DOSE; MONOTHERAPY; NEPHELOMETRY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; TUBERCULIN TEST;

AGED; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; CALCIUM; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNOGLOBULIN M; INFLUENZA VACCINES; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTMENOPAUSE; PROGESTERONE; RHEUMATOID FACTOR; SINGLE-BLIND METHOD; TUBERCULIN TEST;

EID: 55349129655     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02186.x     Document Type: Article

References (31)

1. Carlsten H. Immune responses and bone loss: the estrogen connection. Immunol Rev 2005 208 : 194 206.
2. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007 28 : 521 74.
3. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001 1 : 983 93.
4. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994 33 : 735 9.
5. Goemaere S, Ackerman C, Goethals K et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990 17 : 1620 2.
6. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001 2 : 777 80.
7. Forsblad d'Elia H, Larsen A, Mattsson LA et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003 30 : 1456 63.
8. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 31 : 315 24.
9. Elwing H, Nygren H. Diffusion in gel-enzyme linked immunosorbent assay (DIG-ELISA): a simple method for quantitation of class-specific antibodies. J Immunol Methods 1979 31 : 101 7.
10. Tarkowski A, Nilsson LA. Isotype-specific measurement of rheumatoid factor with reference to clinical features of rheumatoid arthritis. J Clin Lab Immunol 1983 12 : 129 35.
11. Tarkowski E, Ekelund P, Tarkowski A. Increased systemic T-lymphocyte reactivity in patients with established stroke. J Clin Lab Immunol 1991 35 : 171 6.
12. Arnadottir T, Rieder HL, Trebucq A, Waaler HT. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tuber Lung Dis 1996 77 (Suppl. 1 1 19.
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 38 : 44 8.
14. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980 23 : 137 45.
15. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988 17 : 263 71.
16. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999 103 (2 part 1 282 8.
17. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999 42 : 328 37.
18. Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol 1992 144 : 190 202.
19. Yilmazer M, Fenkci V, Fenkci S, Aktepe O, Sonmezer M, Kurtay G. Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women. Hum Reprod 2003 18 : 1531 5.
20. + ratio, and immunoglobulin levels in hemodialysis patients. Ren Fail 2005 27 : 421 4.
21. Todorova M, Kamenov Z, Baleva M, Christov V, Nicolov K. Anticardiolipin antibodies during hormone replacement therapy in healthy postmenopausal women. Maturitas 2004 48 : 393 7.
22. Ahmed SA, Verthelyi D. Antibodies to cardiolipin in normal C57BL/6J mice: induction by estrogen but not dihydrotestosterone. J Autoimmun 1993 6 : 265 79.
23. Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006 65 : 191 4.
24. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007 34 : 272 9.
25. Manyonda IT, Pereira RS, Makinde V, Brincat M, Varma RT. Effect of 17 beta-oestradiol on lymphocyte subpopulations, delayed cutaneous hypersensitivity responses and mixed lymphocyte reactions in post-menopausal women. Maturitas 1992 14 : 201 10.
26. Carlsten H, Verdrengh M, Taube M. Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice. Inflamm Res 1996 45 : 26 30.
27. Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). J Rheumatol 2007 34 : 474 80.
28. Joven BE, Almodovar R, Galindo M, Mateo I, Pablos JL. Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response? Ann Rheum Dis 2006 65 : 699.
29. Helliwell MG, Panayi GS, Unger A. Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol 1984 3 : 39 45.
30. Emery P, Panayi G, Symmons D, Brown G. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 1984 43 : 430 4.
31. Pope RM, Kniker WT, Talal N, Dauphinee M. Delayed type hypersensitivity in patients with rheumatoid arthritis. J Rheumatol 1993 20 : 17 20.